These data comprise the first comprehensive proteomic investigation of the BCR signaling response within CLL cells and reveal unique evidence that these cells undergo adaptive reprogramming of this signaling in response to therapy. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.